These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25950230)

  • 1. Antifibrinolytic Therapy for Cardiac Surgery: An Update.
    Koster A; Faraoni D; Levy JH
    Anesthesiology; 2015 Jul; 123(1):214-21. PubMed ID: 25950230
    [No Abstract]   [Full Text] [Related]  

  • 2. Antifibrinolytic Agents in Cardiac and Noncardiac Surgery: A Comprehensive Overview and Update.
    Gerstein NS; Brierley JK; Windsor J; Panikkath PV; Ram H; Gelfenbeyn KM; Jinkins LJ; Nguyen LC; Gerstein WH
    J Cardiothorac Vasc Anesth; 2017 Dec; 31(6):2183-2205. PubMed ID: 28457777
    [No Abstract]   [Full Text] [Related]  

  • 3. eComment: A comparison of the safety of aprotinin and tranexamic acid in cardiac surgery.
    Koniari I; Apostolakis E; Mandellou M
    Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):101. PubMed ID: 19546299
    [No Abstract]   [Full Text] [Related]  

  • 4. Conference discussion: Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.
    Wahba A; Vonk A; Bidstrup B
    Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):139-40. PubMed ID: 21322159
    [No Abstract]   [Full Text] [Related]  

  • 5. Lessons learned in antifibrinolytic therapy: The BART trial.
    Murkin JM
    Semin Cardiothorac Vasc Anesth; 2009 Jun; 13(2):127-31. PubMed ID: 19622534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.
    Casati V; Guzzon D; Oppizzi M; Bellotti F; Franco A; Gerli C; Cossolini M; Torri G; Calori G; Benussi S; Alfieri O
    J Thorac Cardiovasc Surg; 2000 Sep; 120(3):520-7. PubMed ID: 10962414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aprotinin and lysine analogues in high-risk cardiac surgery.
    Porte RJ; Mallette SV; Burroughs AK
    N Engl J Med; 2008 Sep; 359(11):1181; author reply 1181-2. PubMed ID: 18784112
    [No Abstract]   [Full Text] [Related]  

  • 8. Coronary artery bypass grafting after aprotinin: are we doing better?
    Beckerman Z; Shopen Y; Alon H; Cohen O; Nir RR; Adler Z; Bolotin G
    J Thorac Cardiovasc Surg; 2013 Jan; 145(1):243-8. PubMed ID: 23072702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials.
    Takagi H; Manabe H; Kawai N; Goto SN; Umemoto T
    Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):98-101. PubMed ID: 19380335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.
    Vonk AB; Meesters MI; Schats J; Romijn JW; Jansen EK; Boer C
    Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):135-9. PubMed ID: 21075830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.
    Levi M; Cromheecke ME; de Jonge E; Prins MH; de Mol BJ; Briët E; Büller HR
    Lancet; 1999 Dec; 354(9194):1940-7. PubMed ID: 10622296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Con: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery.
    Beattie WS; Karkouti K
    Anesth Analg; 2006 Dec; 103(6):1360-4. PubMed ID: 17122203
    [No Abstract]   [Full Text] [Related]  

  • 13. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials.
    Carless PA; Moxey AJ; Stokes BJ; Henry DA
    BMC Cardiovasc Disord; 2005 Jul; 5():19. PubMed ID: 15992412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antifibrinolytic agents and repeat open-heart surgery: a comparison of tranexamic acid and low dose aprotinin].
    Ait Houssa M; Selkane C; Amahzoune B; El Bekkali Y; Wahid FA; Moutaki Allah Y; Boulahya A; Ibat D; Drissi M; Azendour H; Elkirat A
    Ann Cardiol Angeiol (Paris); 2007 Dec; 56(6):308-12. PubMed ID: 17976511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The post-BART anti-fibrinolytic dilemma?
    Beattie WS; Karkouti K
    J Cardiothorac Vasc Anesth; 2011 Feb; 25(1):3-5. PubMed ID: 21272775
    [No Abstract]   [Full Text] [Related]  

  • 16. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery.
    Brown JR; Birkmeyer NJ; O'Connor GT
    Circulation; 2007 Jun; 115(22):2801-13. PubMed ID: 17533182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tranexamic acid: how much is enough?
    Fox MA
    Anesth Analg; 2010 Aug; 111(2):580-1; author reply 581. PubMed ID: 20664102
    [No Abstract]   [Full Text] [Related]  

  • 18. Valid comparisons of antifibrinolytic agents used in cardiac surgery.
    Bridges CR
    Circulation; 2007 Jun; 115(22):2790-2. PubMed ID: 17548738
    [No Abstract]   [Full Text] [Related]  

  • 19. [Aprotinin in the control of surgical hemorrhage].
    Rocha E; Antonio Páramo J; Hermida J
    Med Clin (Barc); 1996 Mar; 106(8):307-16. PubMed ID: 8667690
    [No Abstract]   [Full Text] [Related]  

  • 20. Aprotinin versus tranexamic acid: the controversy continues.
    Levy JH
    Transfusion; 2006 Mar; 46(3):319-20. PubMed ID: 16533270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.